C-reactive protein levels and survival in patients with moderate to very severe COPD

BACKGROUND: Serum levels of C-reactive protein (CRP) are increased in patients with COPD and correlate modestly with variables predictive of outcomes. In epidemiologic studies, CRP level is associated with all-cause mortality in patients with mild-to-moderate disease. OBJECTIVE: To determine if CRP levels are associated with survival in patients with moderate to very severe COPD in comparison with other well-known prognostic parameters of the disease. METHODS: In 218 stable patients with COPD, we measured baseline serum CRP level, BODE (body mass index, obstruction, dyspnea, and exercise capacity) index and its components, arterial oxygenation (Pao(2)), inspiratory capacity (IC) to total lung capacity (TLC) ratio, and Charlson comorbidity score. We followed up the patients over time and evaluated the strength of the association between the variables and all-cause mortality. RESULTS: During the follow-up time (median, 36 months; 25th to 75th percentiles, 24 to 50 months), 54 patients (25%) died. CRP levels were similar between survivors and the deceased (median, 3.8 mg/L; 95% confidence interval, 1.9 to 8.1; vs median, 4.5 mg/L; 95% confidence interval, 2.1 to 11.5; p = 0.22) and was not significantly associated with survival. CONCLUSIONS: In this population of patients with clinically moderate to very severe COPD, the level of CRP level was not associated with survival compared with other prognostic clinical tools such as the BODE index, modified Medical Research Council scale, 6-min walk distance, percentage of predicted FEV(1), IC/TLC ratio < 0.25, and Pao(2). Other long-term studies of well-characterized patients with COPD could help determine the exact role of CRP levels as a biomarker in patients with clinical COPD.     

喘可治注射液对慢性阻塞性肺疾病患者呼吸困难程度和运动耐力的影响

目的：观察喘可治注射液中药制剂对脾肾阳虚型慢性阻塞性肺疾病（COPD）稳定期患者呼吸困难程度和运动耐力的影响。方法：将60例中医辨证属脾肾阳虚的稳定期COPD患者随机分为治疗组（30例）和对照组（30例）。对照组给予西医常规方案治疗,治疗组在西医常规方案治疗基础上加用喘可治注射液,疗程均为3个月。采用改良的英国医学研究委员会呼吸困难量表评分（MMRC）和6分钟步行距离（6MWD）指标观察两组患者治疗前后呼吸困难程度和运动耐力的变化。结果 ：经3个月治疗,两组患者治疗后的MMRC与治疗前比较均有下降,差异具有显著性（P〈0.01）,但治疗组下降更明显,与对照组比较差异具有显著性（P〈0.05）。两组患者治疗后6MWD均较治疗前改善,治疗组从（364.93±46.49）m增加到（394.19±49.03）m（P〈0.01）,对照组从（346.31±57.75）m增加到（363.31±48.30）m（P〈0.05）,治疗组6MWD增加更明显,与对照组比较差异具有显著性（P〈0.05）。结论：喘可治注射液可以减轻脾肾阳虚型COPD稳定期患者呼吸困难,提高患者的运动耐力,从而改善患者的生活质量。     

百令胶囊联合注射用细辛脑治疗慢性阻塞性肺疾病急性加重期的疗效观察

目的探讨百令胶囊联合注射用细辛脑治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床效果。方法选择泸州市人民医院2016年4月—2017年5月接收的AECOPD患者116例,随机分为对照组(58例)和治疗组(58例)。对照组静脉滴注注射用细辛脑,24 mg加入5%葡萄糖注射液250 m L,1次/d。治疗组在对照组的基础上口服百令胶囊,5粒/次,3次/d。两组患者连续治疗14 d。观察两组患者临床疗效,比较治疗前后两组患者呼吸困难评分(MMRC)、辅助呼吸肌动用评分、血气分析和肺功能。结果治疗后,对照组患者临床有效率为82.76%,显著低于治疗组的94.83%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者MMRC评分和辅助呼吸肌动用评分均显著低于治疗前(P0.05);且治疗组上述评分比对照组降低的更明显(P0.05)。治疗后,两组患者动脉血氧分压(p O2)、血氧饱和度(Sa O2)均显著高于治疗前,动脉血二氧化碳分压(p CO2)显著降低,同组比较差异具有统计学意义(P0.05);且治疗组血气分析指标改善更明显(P0.05)。治疗后,两组患者用力肺活量(FVC)、第1秒用力呼气量(FEV1)、FEV1占预计值百分比(FEV1%pred)、FEV1/FVC均显著高于治疗前(P0.05);且治疗组患者肺功能显著优于对照组(P0.05)。结论百令胶囊联合注射用细辛脑治疗AECOPD疗效显著,可明显改善血气分析和肺功能,具有一定的临床推广应用价值。     

不同分级慢性阻塞性肺疾病患者胸部定量CT变化的研究

目的 通过分析不同分级慢性阻塞性肺疾病(COPD)稳定期患者胸部定量CT的变化及其与肺功能和症状评分的相关性,探讨其能否做为评估COPD严重程度的方法之一.方法 研究对象为山西医科大学附属大医院呼吸科门诊的90例COPD患者,均行肺功能及胸部定量CT检查,症状评估采用MMRC问卷.根据2011年版GOLD综合评估的方法分为A、B、C和D四组.分别对各组肺功能、胸部定量CT肺气肿评估指标LAA％及症状评分进行相关性分析.结果 ①肺功能:FEV1％pred、VC、DL Adj、FEF75分别在A、B、C和D四组间差异有统计学意义(F分别为59.83,18.56,14.39,16.06,P值均＜0.05);且C、D组均分别小于A和B组,差异均有统计学意义(P值均＜0.05);A、B组间及C、D组间差异均无统计学意义(P值均＞0.05).RV,RV/TLC在A、B、C和D四组间差异无统计学意义(P值均＞0.05).②胸部定量CT:LAA％在CT阈值分别-1 024～-970、-960、-950、-940、-930、-920、-910 HU值下均为一致结果.在-i 024～-910 HU下,A、B、C和D四组间LAA％差异有统计学意义(F=20.22,P＜0.05),两两比较,C和D组LAA％分别大于A和B组,差异均有统计学意义(P值均＜0.05),B组大于A组,差异均有统计学意义(P＜0.05),C组与D组差异无统计学意义(P＞0.05).③相关性:(a)LAA％与肺功能各指标:在-1 024～-910 HU下LAA％与FEV1％ pred、FEF75、DL Adj均呈显著负相关,(r分别为-0.686,-0.509,-0.481,均P＜0.01);与RV和RV/TLC无相关性(P=0.34).(b)LAA％与症状评分:在-1 024～-910 HU下LAA％与MMRC呈显著正相关,(r=0.570,P＜0.01).(c)症状评分与肺功能各项指标:MMRC与FEV1％ pred、FEF75及DL Adj呈显著负相关(r分别为-0.493,-0.330,-0.267,前两者P值均＜0.01,后者P＜0.05).结论 肺气肿可能为A、B两组患者临床症状出现差异的原因之一.COPD患者气流受限严重程度、小气道功能和弥散功能的改变及症状评分与胸部定量CT肺气肿严重程度相关.对于GOLD肺功能分级轻中度以下(FEV1％pred≥50％)的COPD患者,胸部定量CT LAA％评估肺气肿严重程度优于肺功能.胸部定量CT可以做为评估COPD严重程度的方法之一.     

中重度慢性阻塞性肺疾病患者6分钟步行试验及其相关因素分析

目的：探讨中重度COPD稳定期患者6min步行试验（6MWD与肺功能、呼吸困难及生活质量的相关性。方法：选取中重度COPD患者63例,进行6min步行试验并测定肺功能、呼吸困难评分（MMRC）、生活质量（SGRQ）等指标。结果：FEV1％、MMRC、SGRQ总评分及活动能力评分、社交心理影响评分与6min步行距离（6MWD）相关,多元逐步回归分析表明MMRC及活动能力评分与6MWD相关。结论：中重度COPD患者6MWD与MMRC、FEV1％及SGRQ相关。6min步行试验能反映中重度COPD患者的临床状况。     

Impact of COPD exacerbations on patient-centered outcomes

BACKGROUND: Frequent exacerbations are associated with a faster decline in FEV(1), impaired health status, and worse survival. Their impact and temporal relationship with other outcomes such as functional status, dyspnea, and the multidimensional body mass index, obstruction, dyspnea, exercise capacity (BODE) index remain unknown. HYPOTHESIS: We reasoned that exacerbations affect the BODE index and its components, and that changes in the BODE index could be used to monitor the effect of exacerbations on the host. STUDY DESIGN: Prospective observational study in a Veterans Affairs medical center. METHODS: We studied 205 patients with COPD (mean [+/- SD] FEV(1), 43 +/- 15% predicted), and recorded the body mass index, FEV(1) percent predicted, modified Medical Research Council dyspnea scale, 6-min walk distance, and the BODE index at baseline, during the exacerbation, and at 6, 12, and 24 months following the first episode, and documented all exacerbations for 2 years after the first acute exacerbation. RESULTS: From the cohort, 130 patients (63%) experienced 352 exacerbations or (0.85 exacerbations per patient per year); 48 patients (23%), experienced one episode, 82 patients (40%) experienced 2 or more exacerbations, and 50 patients required hospitalization. At study entry, exacerbators had a worse mean baseline BODE index score (4.2 +/- 2.1 vs 3.57 +/- 2.3, respectively; p < 0.03). The BODE index score worsened by 1.38 points during the exacerbation, and remained 0.8 and 1.1 points above baseline at 1 and 2 years, respectively. There was little change in BODE index score at 2 years in nonexacerbators. CONCLUSION: COPD exacerbations negatively impact on the BODE index and its components. The BODE index is a sensitive tool used to assess the impact of exacerbations and to monitor COPD disease progression.     

ICF核心分类联合mMRC用于COPD患者康复效果的研究

目的 应用ICF分类联合mMRC,研究对COPD患者进行干预后康复中效果。方法 选取2017年6月~10月佳木斯大学附属第一医院呼吸内科住院的COPD患者76例为研究对象,通过随机数字表法随机分为试验组和对照组,各38例。试验组依据ICF核心组合分类的身体功能及活动与参与部分收集的信息,给予个体化康复干预措施,对照组进行常规宣教;通过mMRC问卷进行呼吸困难症状评估,6个月后观察所有研究对象用药依从性及呼吸困难改善状况。结果 干预后实验组患者的用药依从性为73.68%优于对照组的18.42%,差异具有统计学意义（P＜0.05）;干预后实验组的呼吸困难症状分级优于对照组,差异具有统计学意义（P＜0.05）。结论 对COPD缓解期患者应用ICF核心分类组合联合mMRC的方法,可提高患者的用药依从性,改善呼吸困难症状。